AGIO Agios Pharmaceuticals, Inc.

48.28
0  -1%
Previous Close 48.74
Open 48.79
Price To book 5.74
Market Cap 2.04B
Shares 42,234,000
Volume 983,245
Short Ratio 13.19
Av. Daily Volume 578,227

SEC filingsSee all SEC filings

  1. 8-K - Current report 17770027
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17770004
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17764756
  4. 8-K - Current report 17683887
  5. S-8 - Securities to be offered to employees in employee benefit plans 17618587

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due by end of 2017.
AG-120
IDH1m Relapsed/Refractory AML - cancer
Phase 2 first data released at EHA meeting June 2016. Updated data due 2H 2017. Pivotal trial design update due 3Q 2017.
AG-348
Pyruvate kinase deficiency
Phase 3 to be initiated 1H 2017
AG-120 and VIDAZA
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continue to enrol through 2016
AG-221 - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
PDUFA date August 30, 2017 under priority review.
Enasidenib (AG-221)
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 initiated December 2016.
AG-120
IDH1 mutant positive cholangiocarcinoma - cancer

Latest News

  1. Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : April 20, 2017
  2. Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : April 19, 2017
  3. Agios Announces Pricing of $250 Million Public Offering of Common Stock
  4. Agios Announces Proposed Offering of Common Stock
  5. 3 Cancer Drug Stocks That Could Make You Rich
  6. Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017
  7. 4 Health Care Charts Signaling Buys: Pfizer, Amgen Included
  8. Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report?
  9. Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene
  10. Biotechs Among 5 Stocks Setting Up for Major Breakouts
  11. These stocks are getting whacked after the GOP unveils its Obamacare replacement
  12. ​Agios CEO touts path from 'a blank piece of paper' to cusp of drug approval
  13. FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation
  14. Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017
  15. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017
  16. Agios Pharmaceuticals 4Q Loss $1.48 Per Share
  17. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
  18. Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
  19. Edited Transcript of AGIO earnings conference call or presentation 16-Feb-17 1:00pm GMT
  20. Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y